PODD
INSULET CORP
NASDAQ · Healthcare · Medical - Devices · US
$141.96
+0.61%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$140.78
From 52W high−59.01%
Volume2.31M
Market cap$9.85B
P/E (TTM)26.5x
P/S (TTM)3.2x
Div yield—
Key dataOct 19, 2026
Open
$140.78
From 52W high
−59.01%
Volume
2.31M
Market cap
$9.85B
ValuationView details →
P/E (Fwd)
19.4x
EV/EBITDA
15.6x
P/E (TTM)
26.5x
RSI (14)
55.8
MomentumView details →
1D Return
+0.61%
YTD Return
−50.31%
SummaryUpdated Jun 1, 2026
Insulet Corporation (NASDAQ:PODD) is a medical device company founded in 2000 and headquartered in Acton, Massachusetts. The company went public in 2007 and has established itself as a leading innovator in diabetes care technology. Insulet specializes in developing, manufacturing, and selling tubeless insulin delivery systems for people with insulin-dependent diabetes. The company has grown from a startup focused on revolutionizing insulin pump technology to a global leader serving over 500,000 customers worldwide, with nine consecutive years of 20%+ revenue growth through 2024.
Similar companies
Latest newsMore news →
Insulet announced the U.S. full market release of Omnipod Discover, a web-based data platform for Omnipod 5 users, caregivers and healthcare providers.8d agoInsulet Corporation announced it will report its third quarter 2026 financial results on November 4, 2026, before market open, with a conference call at 8:00 a.m. Eastern Time.19d agoInsulet Corporation issued guidance for Q3 2026 and full-year 2026 revenue growth, while cutting full-year revenue expectations due to weaker Type 2 diabetes user retention.75d ago